Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression

Abstract

These findings represent a guide for the design of future medication strategy and may be useful in guiding the use of BV in combination with NVP-BHG712 in patients with resistance or intolerance ovarian cancer.